Poxel SA
http://www.poxel.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Poxel SA
Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt
The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.
Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study
A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.
Stock Watch: Poxel Passes Go…But To Where?
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice